Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.08 | 0.35 | -73.27 |
| FCF Yield | -32.40% | -19.14% | -7.90% | -0.99% |
| EV / EBITDA | -2.48 | -3.39 | -10.10 | -93.58 |
| Quality | ||||
| ROIC | -172.50% | -66.32% | -81.51% | -63.53% |
| Gross Margin | 100.00% | 80.24% | 73.57% | -2,289.38% |
| Cash Conversion Ratio | 0.62 | 0.90 | 0.83 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -34.29% | 52.73% | – | – |
| Free Cash Flow Growth | -2.35% | 1.64% | 31.08% | -52.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 1.46 | 0.73 | 1.38 |
| Interest Coverage | 0.00 | 0.00 | -59.50 | -972.13 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -357.90 | -299.35 | -470.48 | -10.57 |